



## Insights Into Advanced Endometrial Cancer (aEC) Saturday, February 24, 2024

Chair: John Chung-Kai Chan, MD

### AGENDA

| Time (MST)   | Topic   |
|--|---|
| 9.00 AM – 9.15 AM<br>(15 min)                                      | <b>Introduction</b> <ul style="list-style-type: none"> <li>• Program overview</li> <li>• Baseline ARS questions</li> </ul>  |
| 9.15 AM – 10.25 AM<br>(30-min presentation;<br>40-min discussion)  | <b>Frontline Treatment of aEC</b> <ul style="list-style-type: none"> <li>• Overview of current first-line data <ul style="list-style-type: none"> <li>– Factors guiding first-line therapy <ul style="list-style-type: none"> <li>▪ Molecular characterization and mutational testing <ul style="list-style-type: none"> <li>• Molecular subtypes</li> </ul> </li> </ul> </li> <li>– Recent updates and ongoing studies <ul style="list-style-type: none"> <li>▪ NRG-GY018</li> <li>▪ RUBY</li> <li>▪ DUO-E</li> <li>▪ LEAP-001</li> </ul> </li> </ul> </li> <li>• Reaction and discussion</li> </ul>   |
| 10.25 AM – 10.40 AM<br>(15 min)                                    | <b>Break</b>  |
| 10.40 AM – 11.50 AM<br>(30-min presentation;<br>40-min discussion) | <b>Treatment of Recurrent aEC</b> <ul style="list-style-type: none"> <li>• ARS questions</li> <li>• Overview of current relapsed/refractory data <ul style="list-style-type: none"> <li>– Factors guiding second-line and subsequent therapies <ul style="list-style-type: none"> <li>▪ Molecular characterization</li> <li>▪ Prior immunotherapy <ul style="list-style-type: none"> <li>• Impact of chemotherapy + immunotherapy on sequencing of agents</li> </ul> </li> <li>▪ Biomarker-directed therapies for mismatch repair-proficient aEC <ul style="list-style-type: none"> <li>• KEYNOTE-775/Study 309: lenvatinib + pembrolizumab <ul style="list-style-type: none"> <li>– Key trial outcomes (OS, PFS, ORR, AEs) <ul style="list-style-type: none"> <li>▪ Final OS readout: Makker V, et al. <i>J Clin Oncol.</i> 2023;41:2904-2910</li> </ul> </li> <li>– Health-related quality of life</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> |

|                                 |   |
|---------------------------------|---|
|                                 | <ul style="list-style-type: none"> <li>▪ Lorusso D, et al. <i>Ann Oncol.</i> 2022;33(suppl 5):S391-S392. Abstract 20MO</li> <li>- AE management <ul style="list-style-type: none"> <li>▪ Makker V, et al. <i>Oncologist.</i> 2021;26:e1599-e1608</li> <li>▪ Dose modifications</li> <li>▪ GI toxicity and hypertension management</li> </ul> </li> <li>• Reaction and discussion</li> </ul> |
| 11.50 AM – 12.00 PM<br>(10 min) | <b>Key Takeaways and Meeting Evaluation</b>   |